Monday, September 12, 2016 3:10:18 PM
Sleep Apnea trials seem to be a lot more straightforward, and I think that's the direction RespireRx will likely proceed next. The trial they're proposing will be for Central Sleep Apnea in patients who are on chronic opioids for pain, so you will get the double benefit that Ampakines have for both Central SA and for opioid induced RD.
CX-1739 previously showed phenomenal efficacy in the Central SA cohort in its SA trial, stunning efficacy, virtually removing all SA symptoms in that cohort. It was only a small cohort within the trial, but the efficacy was incredible. CX-1739 also worked well in Mixed Sleep Apnea (SA with both Central (brain mediated) and obstructive components).
The rationale for why Ampakines work so well in Central SA is very clear because, unlike Obstructive SA, the Central type is caused directly at the area of the brain where Ampakines function, at the AMPA receptors in the brain's control center for respiratory drive (pre-Botzinger Complex), which like the hippocampus, is jam packed with AMPA receptors.
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM